secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0001104659-24-115444
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance updates corporate presentation with Q3 2024 financials and pipeline status
--------------------------------------------------------------------------------

- Cash and investments of ~$404M as of Sept 30, 2024; Q3 product revenue of $58.6M.
- FY 2024 product revenue guidance reaffirmed at $160–$165M.
- 56 Authorized Treatment Centers (ATCs) as of Nov 7, 2024; over 140 Amtagvi patients treated.
- More than 250 million U.S. patient lives covered by payer policies.
- Pipeline includes ongoing TILVANCE-301 Phase 3 trial in frontline advanced melanoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924115444/0001104659-24-115444-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924115444/tm2427860d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-115444

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer